Contents


Central Nervous System


Drug Delivery Across the Blood–Brain Barrier – Current Realities and Future Expectations Tahmina Bahar Syeda,1


Omid Sadeghi-Alavijeh2 and Peter Hoffmann3


1. Pharmidex Pharmaceutical Services Ltd; 2. Pembroke College, Medical Sciences, Oxford University; 3. Genzyme Pharmaceuticals, Cambridge, MA


World-leading CNS and ADMET Solutions Pharmidex


Screening


Differential Anchorage Probes for High-content Screening Bruno Brisson


Chief Business Officer, Fluofarma


Influence of Drug Binding Kinetics on Pharmacodynamic Properties David C Swinney


Director, Virology Biochemical Pharmacology, Roche Palo Alto


Brain Availability Is the Key Parameter for Optimising the Permeability of Central Nervous System Drugs


Hinnerk Boriss CEO, Sovicell GmbH


Nanotechnology


MEDITRANS – An Integrated Project Focusing on Targeted Nanomedicines Sponsored by the European Commission’s Framework Programme 6


Twan Lammers,1,2 William Dawson3 and Gert Storm1


1. Department of Pharmaceutics, Utrecht University; 2. Department of Experimental Molecular Imaging, RWTH Aachen University; 3. Infuturia Group AG


Logistics and Transportation


Geodis Pharmaceutical Strategy – ‘Cross-divisional Integrated Solutions’ Martin Svantesson


Global Supply Chain Management, Geodis Wilson


Generic Assays in G-protein-coupled Receptor Drug Discovery Chris J van Koppen


Department of Molecular Pharmacology and Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Oss Proteomics


Primary Malignant Brain Tumours – Current and Potential Impact of Proteomics-based Analysis Aaron Gajadhar,1


Leori V DeSouza,2 KWM Siu2 and Abhijit Guha1,3


1. Arthur and Sonia Labatts Brain Tumour Center, Sick Kids Hospital Research Institute, University of Toronto; 2. Department of Chemistry, and Centre for Research in Mass Spectrometry, York University, Toronto; 3. Division of Neurosurgery, Western Hospital, University of Toronto


Genomics


Personal Genetics – Lessons Learned and the Opportunities Ahead Linda Avey


Founder, and Executive Director, Brainstorm Research Foundation 6 77 73 69 68 63 58 53 50 49 45


DRUG DISCOVERY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84